



[The Virtual Assessment in Lewy Body Dementia: Pandemic and Beyond Webinar Series](#)

Needs Assessment The COVID-19 pandemic necessitated transition of care to telemedicine due to public health concerns. Those with LBD represent a population vulnerable to the complications of COVID-19 given advanced age and the clinical features inherent to LBD. While the call for telemedicine during COVID-19 is clear, it is less clear how in-office diagnosis and care translates to virtual care in this population.

Target Audience This webinar series is intended for healthcare professionals engaged in the care of patients living with Lewy body dementia and who wish to address this need.

Webinar #1: The approach to clinical care via telemedicine – A Case Based Discussion

Date: March 4, 2021 **Time:** 3pm – 4pm ET

[Register now!](#)

Case 1: Making and Delivering the diagnosis of a more ambiguous case, where the diagnosis is less clear

Case 2: Follow-up visits, engaging care partners, and providing support while working with technology challenges

Presenter: Jori Fleisher, MD, MSCE
Associate Professor, Movement Disorders
Rush Medical College
Rush University

Presenter: Karen Marder, MD, MPH
Sally Kerlin Professor of Neurology
Columbia University Medical Center
New York, NY

Moderator: Katherine Amodeo, MD
Department of Neurology,
Westchester Medical Center
Poughkeepsie, NY

At the conclusion of the activity, learners should be able to:

- Demonstrate an increased knowledge of LBD symptoms and treatment options.
- Discuss the approach of virtual care in LBD with respect to in-person visits.
- Discuss the challenges when assessing motor and non-motor features via telehealth.
- Discuss how to deliver a diagnosis via a telehealth appointment.
- Compare and contrast the differences in delivering a case via telehealth via an in-person diagnosis.
- Outline the various technology challenges a person living with LBD or their care partners may encounter when being seen via televisit
- List solutions to challenges of telehealth appointments and technology challenges.



JOINTLY ACCREDITED PROVIDER
INTERPROFESSIONAL CONTINUING EDUCATION

Accreditation Statement In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Lewy Body Dementia Association. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 *AMA PRA Category 1 credit™*. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

Allied healthcare professionals Participants will receive a Certificate of Attendance stating this program is designated for 1.0 *AMA PRA Category 1 Credit™*. This credit is accepted by the AANP and the AAPA.

This activity is supported through an educational grant from Acadia Pharmaceuticals Inc.
There is no fee for this educational activity.

Disclosure of Conflicts of Interest Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.